Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients

Bristol-Myers Squibb & Co BMY and 2seventy bio Inc TSVT announced the first publication and presentation of results from the KarMMa-3 Phase 3 study evaluating Abecma (idecabtagene vicleucel) in The New England Journal of Medicine.
The study compared Abecma with standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy.
At a median follow-up of 18.6 months, Abecma demonstrated a clinically meaningful and statistically significant improvement in progression-free survival compared with standard regimens, with a median PFS of 13.3 months vs. 4.4 months, representing a 51% reduction in risk of disease progression or death.
The overall response rate also met statistical significance, with 71% treated with Abecma achieving a response and 39% achieving a complete response or stringent complete response.
Also Read: 2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy.
In comparison, 41% who received standard regimens achieved a response, with 5% experiencing a complete response or stringent complete response.
Responses with Abecma were durable, with a median duration of 14.8 months compared with 9.7 months for standard regimens.
Bristol-Myers Squibb and 2seventy bio intend to include these data in a planned supplemental Biologics License Application submission to the FDA in 2023.
Price Action: TSVT shares are down 0.23% at $13.02 on the last check Friday.